PubMed Health⌕ Search

Biomedical subjects

A Baudoux

Publications and source records attributed to A Baudoux.

7 recordsLinked to original sources
PubMed1989

Adjuvant treatment with high dose medroxyprogesterone acetate in node-negative early breast cancer. A 3-year interim report on a randomized trial (I).

After initial surgery, 240 pre-, peri- or postmenopausal patients with early node-negative breast carcinoma were randomized to receive either no hormone therapy or adjuvant therapy with medroxyprogesterone acetate at high dosage (HD-MPA; 500 mg IM per day times 28 or 500 mg intramuscularly (i.m.) 5 days a week for 5 weeks then 500 mg i.m. twice weekly for the 5 following months. After a median follow-up time of 3 years, relapse-free survival and overall survival appeared significantly improved in the HD-MPA arm. Side effects were tolerable.

Adult↗
PubMed1980

[Scintigraphy of biliary system (author's transl)].

Hepatobiliary functional scintigraphy (HBFS) using 99m Tc-labeled Diethyl-IDA was tested in 84 patients suffering from various hepatic and bile duct disorders. The investigated pathologies were: gall bladder dysfunction, parital bile duct obstruction, total obstruction, hepatocellular disease, cirrhosis and drug induced cholostastis. The diagnosis accuracy of the method was found to be 95 %, and the method proved to be useful for guiding the clinician in selecting those additional investigation techniques most apt to define the etiology of the pathological condition accurately. In conclusion, the non-invasive character of the technique, its usefulness even in the presence of elevated bilirubin levels and the information yielded by HBFS make it a method of choice to be placed in the beginning of the test series liver or duct patients are submitted to.

Acetates↗
PubMed1978

[Intestinal tolerance in mice after low dose rate 60CO irradiation. Implications for radiotherapy].

Influence of absorbed dose rate has been studied in BALB/c mice for early intestinal tolerance. After selective abdominal irradiation, LD50 at 5.5 days increases from 12.36 to 20.22 and 21.79 Gy when dose rate decreases from 0.61 to 0.054 and 0.026 Gy/mn. LD50 at 6.5 days increases from 12.05 to 19.22 and 21.58 Gy respectively. The LD50 ratios are then 1.6 and 1.8 for both endpoints. After total body irradiation. LD50 at 5.5 days increases from 9.92 to 15.20and 16.83 Gy when dose rate decreases from 0.56 to 0.049 and 0.024 Gy/mn. The corresponding LD50 ratios, i.e. 1.5 and 1.7, are then similar to the former ones. Increase of LD50 when decreasing dose rate is in agreement with that expected taking into account only repair of sublethal lesions, for the generally accepted cellular models.

Animals↗
PubMedDate not supplied

Improvement of hematological and general tolerance to CMF by high-dose medroxyprogesterone acetate (HD-MPA) adjuvant treatment for primary node positive breast cancer (analysis of 100 patients).

In a prospective randomized trial comparing CMF to CMF + HD-MPA for primary node positive breast cancer patients, the authors evidenced clear improvement of hematological tolerance (especially of WBC - granulocytes counts) to chemotherapy in the group receiving also hormonotherapy. The design of the trial allowed to give the patients overall high doses of CMF therapy in both arms; in the group receiving HD-MPA significantly higher doses of CMF could be administered (96.3-97.8% for CMF + HD-MPA treated patients vs 89.7-91.1% for CMF alone treated patients). The menopausal status did not influence the results.

Adult↗